Herman Mann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4427493/publications.pdf

Version: 2024-02-01

101	2,884	23	52
papers	citations	h-index	g-index
116	116	116	3808
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study. Frontiers in Immunology, 2022, 13, 811045.	2.2	2
2	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. Rheumatology International, 2022, 42, 803-814.	1.5	3
3	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology, 2022, 61, 4741-4751.	0.9	6
4	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. Frontiers in Medicine, 2022, 9, .	1.2	5
5	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. Rheumatology, 2021, 60, 1823-1831.	0.9	4
6	Interleukin-35 in idiopathic inflammatory myopathies. Cytokine, 2021, 137, 155350.	1.4	3
7	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. Rheumatology, 2021, 60, 5060-5072.	0.9	6
8	Clinical Trials in Myositis: Where Do We Stand?. Current Treatment Options in Rheumatology, 2021, 7, 222-242.	0.6	0
9	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research and Therapy, 2021, 23, 173.	1.6	8
10	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. Clinical and Experimental Rheumatology, 2021, 39, 1021-1032.	0.4	1
11	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA. Rheumatology, 2020, 59, 1640-1650.	0.9	18
12	O33â€fEarlier cancer diagnosis after myositis onset is associated with improved long term survival: results from UK, French and Czech cohorts. Rheumatology, 2020, 59, .	0.9	0
13	Alterations in activin A–myostatin–follistatin system associate with disease activity in inflammatory myopathies. Rheumatology, 2020, 59, 2491-2501.	0.9	15
14	Treatment response and drug retention rates in 24 195 biologic-na \tilde{A} -ve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2019, 78, 1536-1544.	0.5	58
15	Efficacy and Safety of Subcutaneous Secukinumab 150Âmg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. Rheumatology and Therapy, 2019, 6, 393-407.	1.1	53
16	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. Rheumatology International, 2019, 39, 1037-1043.	1.5	6
17	FRIO403â€HIGH BASELINE PATIENT'S COMPARED WITH EVALUATOR'S GLOBAL ASSESSMENT IS ASSOC WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS – DATA FROM THE EUROSPA COLLABORATION. , 2019, , .	IATED	0
18	FRIO404â€POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN		1

COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION., 2019, , .

#	Article	IF	CITATIONS
19	AB0752 \hat{a} \in DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÃVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE \hat{a} \in " RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		0
20	AB0687 \hat{a} \in EFFECTIVENESS OF SPECIALIZED AND INTENSIVE ADL TRAINING IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES \hat{a} \in " PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY., 2019,,.		0
21	SAT0391â€REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK. , 2019, , .		0
22	FRI0107â€THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRY. , 2019, , .		0
23	AB0676â€BODY COMPOSITION IN MYOSITIS PATIENTS AND THE ASSOCIATION WITH DISEASE SPECIFIC FEATURES, PHYSICAL ACTIVITY AND PLASMA LEVELS OF INFLAMMATORY CYTOKINES. , 2019, , .		0
24	FRIO378â€DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? â€" RESULTS FROM THE EUROSPA RESEARCH COLLABORATION., 2019,,.		3
25	AB0660â€SEXUAL HEALTH IMPAIRMENT IN WOMEN WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019,	, .	0
26	FRIO453â€DOES DISCORDANCE BETWEEN BASELINE PATIENT'S AND EVALUATOR'S GLOBAL ASSESSM DISEASE ACTIVITY IMPACT RETENTION AND REMISSION RATES OF TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS? DATA FROM THE EUROSPA RESEARCH COLLABORATION., 2019,,.	IENT OF	0
27	Arthritis in Idiopathic Inflammatory Myopathies. Current Rheumatology Reports, 2019, 21, 70.	2.1	10
28	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clinical Rheumatology, 2018, 37, 2055-2062.	1.0	23
29	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the Rheumatic Diseases, 2018, 77, 602-611.	0.5	51
30	Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Annals of the Rheumatic Diseases, 2018, 77, 55-62.	0.5	100
31	CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study. Journal of Rheumatology, 2018, 45, 22-31.	1.0	17
32	The role of imaging in evaluating patients with idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2018, 36 Suppl 114, 74-81.	0.4	4
33	Immuneâ€Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA–DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis and Rheumatology, 2017, 69, 1090-1099.	2.9	41
34	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	2.9	52
35	08.48â€Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
36	THU0113â€Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal c-reactive protein. , 2017, , .		0

#	Article	IF	CITATIONS
37	08.49â€Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients – preliminary data from a single-centre controlled study. , 2017, , .		O
38	FRIO450â€Commonalities and differences in data collection across european spondyloarthritis registries. , 2017, , .		0
39	FRI0399â€Efficacy of an intensive 24-week physiotherapy programme in patients with systemic sclerosis - preliminary data from a single-center controlled study. , 2017, , .		0
40	SAT0358â€Decreased body fat, lean body mass and bone mineral density in patients with systemic sclerosis are associated with disease activity and physical activity., 2017,,.		0
41	MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2017, 29, 623-631.	2.0	23
42	The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis – a cohort study. Arthritis Research and Therapy, 2017, 19, 5.	1.6	15
43	08.01â€Heat shock protein 90 is increased in muscle tissue and plasma in idiopathic inflammatory myopathies. , 2017, , .		0
44	08.47â€Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0
45	02.39â€Clusterin is increased in idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
46	THU0058â€S100A11 protein is up-regulated in patients with idiopatic inflammatory myopathies and is associated with disease activity., 2017, , .		0
47	AB0653â€Efficacy of an intensive 24-week physiotherapy programme in myositis patients - preliminary data from a single-center controlled study. , 2017, , .		0
48	02.30â€High levels of mir-451a differentiate patients with clinically suspect arthralgia from healthy controls. , 2017, , .		0
49	AB1034â€Scoring systems of muscle mri in idiopathic inflammatory myopathies. , 2017, , .		0
50	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE, 2017, 12, e0183420.	1.1	32
51	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 â \in year: a propensity score-matched cohort study. Annals of the Rheumatic Diseases, 2016, 75, 96-102.	0.5	61
52	AB0952â€Serum Visfatin and Resistin, but Not Adiponectin or Leptin, Are Associated with Ultrasound Synovitis in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1227.1-1227.	0.5	0
53	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2016, 18, 156.	1.6	4
54	SAT0068â€Circulating MIR-126 Is A Marker of Disease Activity in Patients with Early RA but Does Not Differentiate Patients at Risk of Developing RA. Annals of the Rheumatic Diseases, 2016, 75, 689.2-689.	0.5	0

#	Article	IF	CITATIONS
55	FRIO544 Impact of Education in Musculoskeletal Ultrasonography: Good To Excellent Reliability Results in Modified US7 Scoring System after One Year of Continuing Education since Basic or Intermediate Level of Training. Annals of the Rheumatic Diseases, 2016, 75, 637.1-637.	0.5	0
56	AB0599â€Interleukin-35 in Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2016, 75, 1109.2-1109.	0.5	0
57	FRIO532â€Association between The 7-Joint Ultrasound Score (US7S) and Physical Function in Rheumatoid Arthritis: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 632.1-632.	0.5	0
58	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 124.	1.6	48
59	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.5	127
60	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS ONE, 2016, 11, e0165498.	1.1	14
61	Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. Clinical and Experimental Rheumatology, 2016, 34, 222-9.	0.4	2
62	SATO436â€Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: Artemis, a Randomized, Treatment Delayed-Start Trial. Annals of the Rheumatic Diseases, 2015, 74, 817.3-818.	0.5	3
63	SAT0250â€A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective and Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis Over Two Years: A Propensity Score-Matched Cohort Study. Annals of the Rheumatic Diseases, 2015, 74, 749.2-749.	0.5	2
64	FRIO592â€Serum Calprotectin is Associated with Ultrasound-Determined Active Synovitis in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 642.2-642.	0.5	0
65	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 252.	1.6	60
66	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	6.3	722
67	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. Biomarkers, 2015, 20, 47-51.	0.9	12
68	Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology, 2015, 54, 2010-2014.	0.9	55
69	Dr. Vencovsk $\tilde{A}^{1}\!\!/_{2}$, <i>et al</i> reply. Journal of Rheumatology, 2015, 42, 1061.2-1061.	1.0	0
70	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0132674.	1.1	28
71	Decreased Circulating Visfatin Is Associated with Improved Disease Activity in Early Rheumatoid Arthritis: Data from the PERAC Cohort. PLoS ONE, 2014, 9, e103495.	1.1	25
72	THU0168â€Monotherapy with Biological Disease-Modifying Anti-Rheumatic Drugs-Data from the Czech Registry Attra:. Annals of the Rheumatic Diseases, 2014, 73, 238.2-238.	0.5	0

#	Article	IF	Citations
73	THU0528â€Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 366.1-366.	0.5	1
74	A1.48â€Enhanced expression of CD11c on non-classical CD16+peripheral blood monocytes in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A20.2-A21.	0.5	1
75	SATO349â€A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 719.1-719.	0.5	1
76	Arthritis in Idiopathic Inflammatory Myopathy: Clinical Features and Autoantibody Associations. Journal of Rheumatology, 2014, 41, 1133-1139.	1.0	23
77	The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2014, 16, 468.	1.6	13
78	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1898-1904.	0.5	165
79	A3.30â€Plasma level of HSP70 protein is increased in czech patients with idiopathic inflammatory myopathy. Annals of the Rheumatic Diseases, 2014, 73, A54.1-A54.	0.5	1
80	Inflammatory myopathy associated with statins: report of three cases. Modern Rheumatology, 2014, 24, 366-371.	0.9	7
81	OP0289â€A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheus Trial). Annals of the Rheumatic Diseases, 2014. 73. 171.1-171.	0.5	3
82	FRIO520â€Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2014, 73, 575.3-576.	0.5	0
83	AB0009â€Association of MHC Haplotypes with Idiopathic Inflammatory Myopathy in Cohort of Czech Patients. Annals of the Rheumatic Diseases, 2014, 73, 806.3-806.	0.5	0
84	SAT0188â€Serum Calprotectin (S100A8/9) Correlates with Clinical and Ultrasound Outcomes in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 658.1-658.	0.5	0
85	A3.29â€Micro-RNA molecules are clearly involved in pathogenesis of idiopathic inflammatory myopathy. Annals of the Rheumatic Diseases, 2014, 73, A53.3-A54.	0.5	1
86	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placeboâ€phase trial. Arthritis and Rheumatism, 2013, 65, 314-324.	6.7	514
87	A10.3â€Arthritis in Patients with Idiopathic Inflammatory Myopathies. Annals of the Rheumatic Diseases, 2013, 72, A72.2-A72.	0.5	1
88	A7.3â€Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A48.3-A49.	0.5	0
89	Inflammatory myopathy associated with statins: report of three cases. Modern Rheumatology, 2012, , 1.	0.9	0
90	Anti-Ro52 epitope mapping in inflammatory myopathies. Annals of the Rheumatic Diseases, 2012, 71, A50.1-A50.	0.5	0

#	Article	IF	CITATIONS
91	Resistin in idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2012, 14, R111.	1.6	21
92	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R122.	1.6	69
93	Clinical trials roundup in idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2011, 23, 605-611.	2.0	9
94	The expression regulation of the HSPA1B gene in patients with myositis is not dependent on the presence of HLA-DRB1*03 risk allele. Annals of the Rheumatic Diseases, 2011, 70, A19-A20.	0.5	1
95	Serum levels of interferon do not correlate with disease activity in patients with dermatomyositis/polymyositis. Annals of the Rheumatic Diseases, 2011, 70, 879-880.	0.5	17
96	The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. Rheumatology, 2011, 50, 1766-1772.	0.9	35
97	Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Annals of the Rheumatic Diseases, 2011, 70, 1822-1825.	0.5	112
98	Treatment-resistant inflammatory myopathy. Best Practice and Research in Clinical Rheumatology, 2010, 24, 427-440.	1.4	10
99	Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis. Immunology Letters, 2010, 128, 124-130.	1.1	35
100	Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2009, 68, 836-843.	0.5	95
101	Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clinical Rheumatology, 2008, 27, 1005-1013.	1.0	25